Boehringer Ingelheim and Pfizer close animal health divestment deal
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has closed its acquisition of part of Pfizer's Fort Dodge animal health business that was sold to satisfy antitrust laws surrounding the US firm's buyout of Wyeth.